Upexi UPXI Gain On The Sale Of Vitamedica And Income From Discontinued Operations
Gain On The Sale Of Vitamedica And Income From Discontinued Operations at other companies
Other financials
Where this comes from
Reported directly by Upexi in its filing.
Tagged under the XBRL concept upxi:GainOnTheSaleOfVitamedicaAndIncomeFromDiscontinuedOperations.
The official record: Upexi’s 10-K, filed September 24, 2025, on SEC EDGAR. View the filing →
Ask your AI about Upexi's gain on the sale of vitamedica and income from discontinued operations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Upexi's gain on the sale of vitamedica and income from discontinued operations?
- Upexi (UPXI) reported gain on the sale of vitamedica and income from discontinued operations of $0 in Q2 2025.
- How has Upexi's gain on the sale of vitamedica and income from discontinued operations changed year-over-year?
- Upexi's gain on the sale of vitamedica and income from discontinued operations decreased by 100.0% year-over-year, from $487.13K to $0.
- What does gain on the sale of vitamedica and income from discontinued operations mean?
- This metric captures the non-recurring financial gain realized from the divestiture of a specific business unit or subsidiary. It provides insight into the company's capital recycling strategy and the impact of portfolio optimization on net income.